|
1
|
Bird SA and Boyd K: 9. Multiple myeloma:
An overview of management. Palliat Care Soc Pract.
13(1178224219868235)2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Nijhof IS, van de Donk NWCJ, Zweegman S
and Lokhorst HM: Current and new therapeutic strategies for
relapsed and refractory multiple myeloma: An update. Drugs.
78:19–37. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Shah UA and Mailankody S: Emerging
immunotherapies in multiple myeloma. BMJ. 370(m3176)2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Pinto V, Bergantim R, Caires HR, Seca H,
Guimarães JE and Vasconcelos MH: Multiple Myeloma: Available
therapies and causes of drug resistance. Cancers (Basel).
12(407)2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Cowan AJ, Green DJ, Kwok M, Lee S, Coffey
DG, Holmberg LA, Tuazon S, Gopal AK and Libby EN: Diagnosis and
management of multiple myeloma: A review. JAMA. 327:464–477.
2022.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Delforge M, Vlayen S and Kint N:
Immunomodulators in newly diagnosed multiple myeloma: Current and
future concepts. Expert Rev Hematol. 14:365–376. 2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Burgess J, Ferdousi M, Gosal D, Boon C,
Matsumoto K, Marshall A, Mak T, Marshall A, Frank B, Malik RA and
Alam U: Chemotherapy-Induced peripheral neuropathy: Epidemiology,
pathomechanisms and treatment. Oncol Ther. 9:385–450.
2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Tageja N: Lenalidomide-current
understanding of mechanistic properties. Anticancer Agents Med
Chem. 11:315–326. 2011.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Cives M, Simone V, Brunetti O, Longo V and
Silvestris F: Novel lenalidomide-based combinations for treatment
of multiple myeloma. Crit Rev Oncol Hematol. 85:9–20.
2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Quach H, Kalff A and Spencer A:
Lenalidomide in multiple myeloma: Current status and future
potential. Am J Hematol. 87:1089–1095. 2012.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Jabbour E, Thomas D, Kantarjian H, Zhou L,
Pierce S, Cortes J and Verstovsek S: Comparison of thalidomide and
lenalidomide as therapy for myelofibrosis. Blood. 118:899–902.
2011.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Kotla V, Goel S, Nischal S, Heuck C, Vivek
K, Das B and Verma A: Mechanism of action of lenalidomide in
hematological malignancies. J Hematol Oncol. 2(36)2009.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Tawara K, Scott H, Emathinger J, Ide A,
Fox R, Greiner D, LaJoie D, Hedeen D, Nandakumar M, Oler AJ, et al:
Co- Expression of VEGF and IL-6 Family Cytokines is Associated with
Decreased Survival in HER2 Negative Breast Cancer Patients:
Subtype-Specific IL-6 Family Cytokine-Mediated VEGF Secretion.
Transl Oncol. 12:245–255. 2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Matthes T, Manfroi B and Huard B:
Revisiting IL-6 antagonism in multiple myeloma. Crit Rev Oncol
Hematol. 105:1–4. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Zhou J, Shen Q, Lin H, Hu L, Li G and
Zhang X: Decitabine shows potent anti-myeloma activity by depleting
monocytic myeloid-derived suppressor cells in the myeloma
microenvironment. J Cancer Res Clin Oncol. 145:329–336.
2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Díaz T, Rodríguez V, Lozano E, Mena MP,
Calderón M, Rosiñol L, Martínez A, Tovar N, Pérez-Galán P, Bladé J,
et al: The BET bromodomain inhibitor CPI203 improves lenalidomide
and dexamethasone activity in in vitro and in vivo models of
multiple myeloma by blockade of Ikaros and MYC signaling.
Haematologica. 102:1776–1784. 2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Kulikov AV, Shilov ES, Mufazalov IA,
Gogvadze V, Nedospasov SA and Zhivotovsky B: Cytochrome c: The
Achilles' heel in apoptosis. Cell Mol Life Sci. 69:1787–1797.
2012.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Li L, Hua Y, Dong M, Li Q, Smith DT, Yuan
M, Jones KR and Ren J: Short-term lenalidomide (Revlimid)
administration ameliorates cardiomyocyte contractile dysfunction in
ob/ob obese mice. Obesity (Silver Spring). 20:2174–2185.
2012.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Zhou L, Huang X, Niesvizky R, Pu Z and Xu
G: Caspase-8 regulates the antimyeloma activity of bortezomib and
lenalidomide. J Pharmacol Exp Ther. 379:303–309. 2021.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Zhou L: Caspase-8: Friend or Foe in
bortezomib/lenalidomide-based therapy for myeloma. Front Oncol.
12(861709)2022.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Felici C, Passarelli A, Cafforio P,
Racanelli V, Leone P and Tucci M: Lenalidomide arrests cell cycle
and modulates PD1-dependent downstream mTOR intracellular signals
in melanoma cells. Melanoma Res. 33:357–363. 2023.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Wong AH, Shin EM, Tergaonkar V and Chng
WJ: Targeting NF-κB signaling for multiple myeloma. Cancers
(Basel). 12(2203)2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Li S, Pal R, Monaghan SA, Schafer P,
Ouyang H, Mapara M, Galson DL and Lentzsch S: IMiD immunomodulatory
compounds block C/EBP{beta} translation through eIF4E
down-regulation resulting in inhibition of MM. Blood.
117:5157–5165. 2011.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Bou Zerdan M, Nasr L, Kassab J, Saba L,
Ghossein M, Yaghi M, Dominguez B and Chaulagain CP: Adhesion
molecules in multiple myeloma oncogenesis and targeted therapy. Int
J Hematol Oncol. 11(IJH39)2022.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Qu X, Mei J, Yu Z, Zhai Z, Qiao H and Dai
K: Lenalidomide regulates osteocytes fate and related
osteoclastogenesis via IL-1β/NF-κB/RANKL signaling. Biochem Biophys
Res Commun. 501:547–555. 2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Cho SF, Lin L, Xing L, Li Y, Wen K, Yu T,
Hsieh PA, Munshi N, Wahl J, Matthes K, et al: The immunomodulatory
drugs lenalidomide and pomalidomide enhance the potency of AMG 701
in multiple myeloma preclinical models. Blood Adv. 4:4195–4207.
2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Castelli R, Cassin R, Cannavò A and Cugno
M: Immunomodulatory drugs: new options for the treatment of
myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 13:1–7.
2013.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Neuber B, Dai J, Waraich WA, Awwad MHS,
Engelhardt M, Schmitt M, Medenhoff S, Witzens-Harig M, Ho AD,
Goldschmidt H and Hundemer M: Lenalidomide overcomes the
immunosuppression of regulatory CD8(+)CD28(-) T-cells. Oncotarget.
8:98200–98214. 2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Richardson K, Keam SP, Zhu JJ, Meyran D,
D'Souza C, Macdonald S, Campbell K, Robbins M, Bezman NA, Todd K,
et al: The efficacy of combination treatment with elotuzumab and
lenalidomide is dependent on crosstalk between natural killer
cells, monocytes and myeloma cells. Haematologica. 108:83–97.
2023.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Bodera P and Stankiewicz W:
Immunomodulatory properties of thalidomide analogs: Pomalidomide
and lenalidomide, experimental and therapeutic applications. Recent
Pat Endocr Metab Immune Drug Discov. 5:192–196. 2011.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Benson DM Jr, Bakan CE, Mishra A,
Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J,
Smith MK, et al: The PD-1/PD-L1 axis modulates the natural killer
cell versus multiple myeloma effect: a therapeutic target for
CT-011, a novel monoclonal anti-PD-1 antibody. Blood.
116:2286–2294. 2010.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Hallett WH, Jing W, Drobyski WR and
Johnson BD: Immunosuppressive effects of multiple myeloma are
overcome by PD-L1 blockade. Biol Blood Marrow Transplant.
17:1133–1145. 2011.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Tamura H, Ishibashi M, Yamashita T,
Tanosaki S, Okuyama N, Kondo A, Hyodo H, Shinya E, Takahashi H,
Dong H, et al: Marrow stromal cells induce B7-H1 expression on
myeloma cells, generating aggressive characteristics in multiple
myeloma. Leukemia. 27:464–472. 2013.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Chen N, Kasserra C, Reyes J, Liu L and Lau
H: Single-dose pharmacokinetics of lenalidomide in healthy
volunteers: Dose proportionality, food effect, and racial
sensitivity. Cancer Chemother Pharmacol. 70:717–725.
2012.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Chen N, Weiss D, Reyes J, Liu L, Kasserra
C, Wang X, Zhou S, Kumar G, Weiss L and Palmisano M: No clinically
significant drug interactions between lenalidomide and
P-glycoprotein substrates and inhibitors: results from controlled
phase I studies in healthy volunteers. Cancer Chemother Pharmacol.
73:1031–1039. 2014.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Chen N, Ye Y, Liu L, Reyes J, Assaf MS,
Kasserra C, Zhou S and Palmisano M: Lenalidomide at therapeutic and
supratherapeutic doses does not prolong QTc intervals in the
thorough QTc study conducted in healthy men. Basic Clin Pharmacol
Toxicol. 113:179–186. 2013.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Larocca A, Bonello F, Gaidano G,
D'Agostino M, Offidani M, Cascavilla N, Capra A, Benevolo G, Tosi
P, Galli M, et al: Dose/schedule-adjusted Rd-R vs continuous Rd for
elderly, intermediate-fit patients with newly diagnosed multiple
myeloma. Blood. 137:3027–3036. 2021.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Lund J, Gruber A, Lauri B, Duru AD,
Blimark C, Swedin A, Hansson M, Forsberg K, Ahlberg L, Carlsson C,
et al: Lenalidomide versus lenalidomide + dexamethasone prolonged
treatment after second-line lenalidomide + dexamethasone induction
in multiple myeloma. Cancer Med. 7:2256–2268. 2018.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Durie BGM, Hoering A, Abidi MH, Rajkumar
SV, Epstein J, Kahanic SP, Thakuri M, Reu F, Reynolds CM, Sexton R,
et al: Bortezomib with lenalidomide and dexamethasone versus
lenalidomide and dexamethasone alone in patients with newly
diagnosed myeloma without intent for immediate autologous stem-cell
transplant (SWOG S0777): A randomised, open-label, phase 3 trial.
Lancet. 389:519–527. 2017.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Mohammad NS, Nazli R, Zafar H and Fatima
S: Effects of lipid based Multiple Micronutrients Supplement on the
birth outcome of underweight pre-eclamptic women: A randomized
clinical trial. Pak J Med Sci. 38:219–226. 2022.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Zou Y, Lin M, Sheng Z and Niu S:
Bortezomib and lenalidomide as front-line therapy for multiple
myeloma. Leuk Lymphoma. 55:2024–2031. 2014.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Joseph NS, Kaufman JL, Dhodapkar MV,
Hofmeister CC, Almaula DK, Heffner LT, Gupta VA, Boise LH, Lonial S
and Nooka AK: Long-Term follow-up results of lenalidomide,
bortezomib, and dexamethasone induction therapy and risk-adapted
maintenance approach in newly diagnosed multiple myeloma. J Clin
Oncol. 38:1928–1937. 2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
McCaughan GJ, Gandolfi S, Moore JJ and
Richardson PG: Lenalidomide, bortezomib and dexamethasone induction
therapy for the treatment of newly diagnosed multiple myeloma: A
practical review. Br J Haematol. 199:190–204. 2022.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Goldschmidt H, Mai EK, Bertsch U, Fenk R,
Nievergall E, Tichy D, Besemer B, Dürig J, Schroers R, von Metzler
I, et al: Addition of isatuximab to lenalidomide, bortezomib, and
dexamethasone as induction therapy for newly diagnosed,
transplantation-eligible patients with multiple myeloma (GMMG-HD7):
Part 1 of an open-label, multicentre, randomised,
active-controlled, phase 3 trial. Lancet Haematol. 9:e810–e821.
2022.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Voorhees PM, Kaufman JL, Laubach J, Sborov
DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ,
Anderson LD Jr, et al: Daratumumab, lenalidomide, bortezomib, and
dexamethasone for transplant-eligible newly diagnosed multiple
myeloma: the GRIFFIN trial. Blood. 136:936–945. 2020.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Attal M, Lauwers-Cances V, Hulin C, Leleu
X, Caillot D, Escoffre M, Arnulf B, Macro M, Belhadj K, Garderet L,
et al: Lenalidomide, bortezomib, and dexamethasone with
transplantation for myeloma. N Engl J Med. 376:1311–1320.
2017.PubMed/NCBI View Article : Google Scholar
|
|
47
|
O'Donnell EK, Laubach JP, Yee AJ, Chen T,
Huff CA, Basile FG, Wade PM, Paba-Prada CE, Ghobrial IM, Schlossman
RL, et al: A phase 2 study of modified lenalidomide, bortezomib and
dexamethasone in transplant-ineligible multiple myeloma. Br J
Haematol. 182:222–230. 2018.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Iida S, Wakabayashi M, Tsukasaki K,
Miyamoto K, Maruyama D, Yamamoto K, Takatsuka Y, Kusumoto S, Kuroda
J, Ando K, et al: Bortezomib plus dexamethasone vs thalidomide plus
dexamethasone for relapsed or refractory multiple myeloma. Cancer
Sci. 109:1552–1561. 2018.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Dimopoulos MA, Laubach JP, Echeveste
Gutierrez MA, Grzasko N, Hofmeister CC, San-Miguel JF, Kumar S,
Labotka R, Lu V, Berg D, et al: Ixazomib maintenance therapy in
newly diagnosed multiple myeloma: An integrated analysis of four
phase I/II studies. Eur J Haematol. 102:494–503. 2019.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Kumar SK, Berdeja JG, Niesvizky R, Lonial
S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, et
al: Ixazomib, lenalidomide, and dexamethasone in patients with
newly diagnosed multiple myeloma: Long-term follow-up including
ixazomib maintenance. Leukemia. 33:1736–1746. 2019.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Facon T, Venner CP, Bahlis NJ, Offner F,
White DJ, Karlin L, Benboubker L, Rigaudeau S, Rodon P, Voog E, et
al: Oral ixazomib, lenalidomide, and dexamethasone for
transplant-ineligible patients with newly diagnosed multiple
myeloma. Blood. 137:3616–3628. 2021.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Patel KK, Shah JJ, Feng L, Lee HC,
Manasanch EM, Olsem J, Morphey A, Huo XJ, Thomas SK, Bashir Q, et
al: Safety and efficacy of combination maintenance therapy with
ixazomib and lenalidomide in patients with posttransplant myeloma.
Clin Cancer Res. 28:1277–1284. 2022.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Richardson PG, Kumar SK, Masszi T, Grzasko
N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, et
al: Final overall survival analysis of the TOURMALINE-MM1 phase III
trial of ixazomib, lenalidomide, and dexamethasone in patients with
relapsed or refractory multiple myeloma. J Clin Oncol.
39:2430–2442. 2021.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Takakuwa T, Yamamura R, Ohta K, Kaneko H,
Imada K, Nakaya A, Fuchida SI, Shibayama H, Matsuda M, Shimazu Y,
et al: Outcomes of ixazomib/lenalidomide/dexamethasone for multiple
myeloma: A multicenter retrospective analysis. Eur J Haematol.
106:555–562. 2021.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Jakubowiak A, Usmani SZ, Krishnan A,
Lonial S, Comenzo RL, Wang J, de Boer C, Deraedt W, Weiss BM,
Schecter JM and Chari A: Daratumumab plus carfilzomib,
lenalidomide, and dexamethasone in patients with newly diagnosed
multiple myeloma. Clin Lymphoma Myeloma Leuk. 21:701–710.
2021.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Kumar SK, Jacobus SJ, Cohen AD, Weiss M,
Callander N, Singh AK, Parker TL, Menter A, Yang X, Parsons B, et
al: Carfilzomib or bortezomib in combination with lenalidomide and
dexamethasone for patients with newly diagnosed multiple myeloma
without intention for immediate autologous stem-cell
transplantation (ENDURANCE): A multicentre, open-label, phase 3,
randomised, controlled trial. Lancet Oncol. 21:1317–1330.
2020.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Jasielec JK, Kubicki T, Raje N, Vij R,
Reece D, Berdeja J, Derman BA, Rosenbaum CA, Richardson P,
Gurbuxani S, et al: Carfilzomib, lenalidomide, and dexamethasone
plus transplant in newly diagnosed multiple myeloma. Blood.
136:2513–2523. 2020.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Roussel M, Lauwers-Cances V, Wuilleme S,
Belhadj K, Manier S, Garderet L, Escoffre-Barbe M, Mariette C,
Benboubker L, Caillot D, et al: Up-front carfilzomib, lenalidomide,
and dexamethasone with transplant for patients with multiple
myeloma: the IFM KRd final results. Blood. 138:113–121.
2021.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Siegel DS, Dimopoulos MA, Ludwig H, Facon
T, Goldschmidt H, Jakubowiak A, San-Miguel J, Obreja M, Blaedel J
and Stewart AK: Improvement in overall survival with carfilzomib,
lenalidomide, and dexamethasone in patients with relapsed or
refractory multiple myeloma. J Clin Oncol. 36:728–734.
2018.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Onda Y, Kanda J, Kaneko H, Shimura Y,
Fuchida SI, Nakaya A, Itou T, Yamamura R, Tanaka H, Shibayama H, et
al: Real-world effectiveness and safety analysis of
carfilzomib-lenalidomide-dexamethasone and
carfilzomib-dexamethasone in relapsed/refractory multiple myeloma:
a multicenter retrospective analysis. Ther Adv Hematol.
13(20406207221104584)2022.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Baertsch MA, Fougereau M, Hielscher T,
Sauer S, Breitkreutz I, Jordan K, Müller-Tidow C, Goldschmidt H,
Raab MS, Hillengass J and Giesen N: Carfilzomib, lenalidomide, and
dexamethasone followed by salvage autologous stem cell transplant
with or without maintenance for relapsed or refractory multiple
myeloma. Cancers (Basel). 13(4706)2021.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Bazarbachi AH, Al Hamed R, Malard F,
Bazarbachi A, Harousseau JL and Mohty M: Induction therapy prior to
autologous stem cell transplantation (ASCT) in newly diagnosed
multiple myeloma: An update. Blood Cancer J. 12(47)2022.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Pulte ED, Dmytrijuk A, Nie L, Goldberg KB,
McKee AE, Farrell AT and Pazdur R: FDA approval summary:
Lenalidomide as maintenance therapy after autologous stem cell
transplant in newly diagnosed multiple myeloma. Oncologist.
23:734–739. 2018.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Liu J, Zhao R, Jiang X, Li Z and Zhang B:
Progress on the application of bortezomib and bortezomib-based
nanoformulations. Biomolecules. 12(51)2021.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Yang MH, Jung SH, Chinnathambi A, Alahmadi
TA, Alharbi SA, Sethi G and Ahn KS: Attenuation of STAT3 signaling
cascade by daidzin can enhance the apoptotic potential of
bortezomib against multiple myeloma. Biomolecules.
10(23)2019.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Medhekar R, Ran T, Fu AZ, Patel S and
Kaila S: Real-world patient characteristics and treatment outcomes
among nontransplanted multiple myeloma patients who received
Bortezomib in combination with Lenalidomide and Dexamethasone as
first line of therapy in the United States. BMC Cancer.
22(901)2022.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Harousseau JL and Mohty M: Daratumumab in
transplant regimens for myeloma? Blood. 136:917–918.
2020.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Goicoechea I, Puig N, Cedena MT, Burgos L,
Cordón L, Vidriales MB, Flores-Montero J, Gutierrez NC, Calasanz
MJ, Ramos MM, et al: Deep MRD profiling defines outcome and unveils
different modes of treatment resistance in standard- and high-risk
myeloma. Blood. 137:49–60. 2021.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Shirley M: Ixazomib: First global
approval. Drugs. 76:405–411. 2016.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Arastu-Kapur S, Anderl JL, Kraus M,
Parlati F, Shenk KD, Lee SJ, Muchamuel T, Bennett MK, Driessen C,
Ball AJ and Kirk CJ: Nonproteasomal targets of the proteasome
inhibitors bortezomib and carfilzomib: A link to clinical adverse
events. Clin Cancer Res. 17:2734–2743. 2011.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Jayaweera SPE, Wanigasinghe Kanakanamge
SP, Rajalingam D and Silva GN: Carfilzomib: A promising proteasome
inhibitor for the treatment of relapsed and refractory multiple
myeloma. Front Oncol. 11(740796)2021.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Jackson GH, Davies FE, Pawlyn C, Cairns
DA, Striha A, Collett C, Hockaday A, Jones JR, Kishore B, Garg M,
et al: Lenalidomide maintenance versus observation for patients
with newly diagnosed multiple myeloma (Myeloma XI): A multicentre,
open-label, randomised, phase 3 trial. Lancet Oncol. 20:57–73.
2019.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Hamnvik OP, Larsen PR and Marqusee E:
Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst.
103:1572–1587. 2011.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Koeppen S: Treatment of multiple myeloma:
Thalidomide-, bortezomib-, and lenalidomide-induced peripheral
neuropathy. Oncol Res Treat. 37:506–513. 2014.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Dalla Torre C, Zambello R, Cacciavillani
M, Campagnolo M, Berno T, Salvalaggio A, De March E, Barilà G, Lico
A, Lucchetta M, et al: Lenalidomide long-term neurotoxicity:
Clinical and neurophysiologic prospective study. Neurology.
87:1161–1166. 2016.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Patrizi A, Venturi M, Dika E, Maibach H,
Tacchetti P and Brandi G: Cutaneous adverse reactions linked to
targeted anticancer therapies bortezomib and lenalidomide for
multiple myeloma: new drugs, old side effects. Cutan Ocul Toxicol.
33:1–6. 2014.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Tinsley SM, Kurtin SE and Ridgeway JA:
Practical management of lenalidomide-related rash. Clin Lymphoma
Myeloma Leuk. 15 (Suppl):S64–S69. 2015.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Shanbhag A, Pritchard ER, Chatterjee K and
Hammond DA: highly probable drug reaction with eosinophilia and
systemic symptoms syndrome associated with lenalidomide. Hosp
Pharm. 52:408–411. 2017.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Dimopoulos MA, Richardson PG, Brandenburg
N, Yu Z, Weber DM, Niesvizky R and Morgan GJ: A review of second
primary malignancy in patients with relapsed or refractory multiple
myeloma treated with lenalidomide. Blood. 119:2764–2767.
2012.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Nojkov B, Signori C, Konda A and Fontana
RJ: Lenalidomide-associated hepatotoxicity-a case report and
literature review. Anticancer Res. 32:4117–4119. 2012.PubMed/NCBI
|
|
81
|
Hussain S, Browne R, Chen J and Parekh S:
Lenalidomide-induced severe hepatotoxicity. Blood.
110(3814)2007.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Facon T, Dimopoulos MA, Dispenzieri A,
Catalano JV, Belch A, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis
NJ, et al: Final analysis of survival outcomes in the phase 3 FIRST
trial of up-front treatment for multiple myeloma. Blood.
131:301–310. 2018.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Benboubker L, Dimopoulos MA, Dispenzieri
A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H,
Bahlis N, et al: Lenalidomide and dexamethasone in
transplant-ineligible patients with myeloma. N Engl J Med.
371:906–917. 2014.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Richardson PG, Jacobus SJ, Weller EA,
Hassoun H, Lonial S, Raje NS, Medvedova E, McCarthy PL, Libby EN,
Voorhees PM, et al: Triplet Therapy, transplantation, and
maintenance until progression in myeloma. N Engl J Med.
387:132–147. 2022.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Nucci M and Anaissie E: Infections in
patients with multiple myeloma in the era of high-dose therapy and
novel agents. Clin Infect Dis. 49:1211–1225. 2009.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Kikuchi T, Kusumoto S, Tanaka Y, Oshima Y,
Fujinami H, Suzuki T, Totani H, Kinoshita S, Asao Y, Narita T, et
al: Hepatitis B virus reactivation in a myeloma patient with
resolved infection who received daratumumab-containing salvage
chemotherapy. J Clin Exp Hematop. 60:51–54. 2020.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Kekre N and Connors JM: Venous
thromboembolism incidence in hematologic malignancies. Blood Rev.
33:24–32. 2019.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Piedra K, Peterson T, Tan C, Orozco J,
Hultcrantz M, Hassoun H, Mailankody S, Lesokhin A, Shah U, Lu S, et
al: Comparison of venous thromboembolism incidence in newly
diagnosed multiple myeloma patients receiving bortezomib,
lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide,
dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis.
Br J Haematol. 196:105–109. 2022.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Bradbury CA, Craig Z, Cook G, Pawlyn C,
Cairns DA, Hockaday A, Paterson A, Jenner MW, Jones JR, Drayson MT,
et al: Thrombosis in patients with myeloma treated in the Myeloma
IX and Myeloma XI phase 3 randomized controlled trials. Blood.
136:1091–1104. 2020.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Bwire R, Freeman J and Houn F: Managing
the teratogenic risk of thalidomide and lenalidomide: An industry
perspective. Expert Opin Drug Saf. 10:3–8. 2011.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Somers GS: Thalidomide and congenital
abnormalities. Lancet. 1:912–913. 1962.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Mueller M and Lewis DJ: Implementation of
a pregnancy prevention programme (PPP) with a controlled
distribution system (CDS) for the generic teratogenic phthalimides
thalidomide, lenalidomide and pomalidomide. Ther Innov Regul Sci.
55:1155–1164. 2021.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Hui JY, Fuchs A and Kumar G: Embryo-fetal
exposure and developmental outcome of lenalidomide following oral
administration to pregnant cynomolgus monkeys. Reprod Toxicol.
114:57–65. 2022.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Zhu YX, Shi CX, Bruins LA, Wang X, Riggs
DL, Porter B, Ahmann JM, de Campos CB, Braggio E, Bergsagel PL and
Stewart AK: Identification of lenalidomide resistance pathways in
myeloma and targeted resensitization using cereblon replacement,
inhibition of STAT3 or targeting of IRF4. Blood Cancer J.
9(19)2019.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Cohen YC, Zada M, Wang SY, Bornstein C,
David E, Moshe A, Li B, Shlomi-Loubaton S, Gatt ME, Gur C, et al:
Identification of resistance pathways and therapeutic targets in
relapsed multiple myeloma patients through single-cell sequencing.
Nat Med. 27:491–503. 2021.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Bukowski K, Kciuk M and Kontek R:
Mechanisms of multidrug resistance in cancer chemotherapy. Int J
Mol Sci. 21(3233)2020.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Mikhael J, Manola J, Dueck AC, Hayman S,
Oettel K, Kanate AS, Lonial S and Rajkumar SV: Lenalidomide and
dexamethasone in patients with relapsed multiple myeloma and
impaired renal function: PrE1003, a PrECOG study. Blood Cancer J.
8(86)2018.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Chen N, Zhou S and Palmisano M: Clinical
pharmacokinetics and pharmacodynamics of lenalidomide. Clin
Pharmacokinet. 56:139–152. 2017.PubMed/NCBI View Article : Google Scholar
|
